{"id":"NCT02714218","sponsor":"Bristol-Myers Squibb","briefTitle":"A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma","officialTitle":"Phase IIIb/IV, Randomized, Double Blinded, Study of Nivolumab 3 mg/kg in Combination With Ipilimumab 1 mg/kg vs Nivolumab 1 mg/kg in Combination With Ipilimumab 3 mg/kg in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-04-04","primaryCompletion":"2017-04-20","completion":"2021-05-28","firstPosted":"2016-03-21","resultsPosted":"2019-04-23","lastUpdate":"2022-06-24"},"enrollment":387,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Melanoma"],"interventions":[{"type":"BIOLOGICAL","name":"Nivolumab 3 mg/kg IV","otherNames":[]},{"type":"BIOLOGICAL","name":"Ipilimumab 1 mg/kg IV","otherNames":[]},{"type":"BIOLOGICAL","name":"Nivolumab 1 mg/kg IV","otherNames":[]},{"type":"BIOLOGICAL","name":"Ipilimumab 3 mg/kg IV","otherNames":[]},{"type":"BIOLOGICAL","name":"Nivolumab 6 mg/kg IV","otherNames":[]}],"arms":[{"label":"Nivolumab 3 mg/kg IV + Ipilimumab 1 mg/kg IV","type":"EXPERIMENTAL"},{"label":"Ipilimumab 3 mg/kg IV + Nivolumab 1 mg/kg IV","type":"EXPERIMENTAL"},{"label":"Nivolumab 6 mg/kg IV + Ipilimumab 1 mg/kg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate two different dose combinations of nivolumab and ipilimumab in the treatment of melanoma.","primaryOutcome":{"measure":"The Percentage of Participants With Drug-Related Grade 3 - 5 Adverse Events (AEs)","timeFrame":"From first dose of study treatment up to primary completion date 20-Apr-2017 (up to approximately 12 months)","effectByArm":[{"arm":"Nivolumab 3 mg/kg IV + Ipilimumab 1 mg/kg IV","deltaMin":32.8,"sd":null},{"arm":"Ipilimumab 3 mg/kg IV + Nivolumab 1 mg/kg IV","deltaMin":45.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0144"},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":57,"countries":["United States","Australia","Canada","Denmark","France","Germany","Israel","Italy","Netherlands","Poland","Russia","Spain","United Kingdom"]},"refs":{"pmids":["39504507","30811280"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":109,"n":180},"commonTop":["Diarrhoea","Pruritus","Fatigue","Asthenia","Nausea"]}}